The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field

Myocardial Infarction Clinical Trial

— TITAN  

Official title:

The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field The TITAN Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04458883
• Other study ID #: 2-010-20
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: July 31, 2025

Study information

• Verified date: May 2023
• Source: University of Aberdeen
• Contact: James Ross, PhD
• Phone: 01224437832
• Email: james.ross[@]abdn.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.

Description:

Aberdeen scientists are at the forefront of a new type of magnetic resonance imaging (MRI), having built in-house the only two available prototypes of Fast Field-Cycling MRI in the world - and these already have clinical imaging capabilities. Fast Field-Cycling MRI switches rapidly over a range of field strengths (0.2 T to 200 µT), providing a T1 dispersion curve. This information is invisible to fixed-field scanners and uncovers unique knowledge about motion and interaction between component molecules within a tissue (i.e. water/fat/proteins). In this application the investigators wish to use their in-house expertise further to extend the capability of our Fast Field-Cycling MRI to perform cardiac imaging by building the first-ever cardiac Fast Field-Cycling MRI coil and develop cardiac pulse sequences with ECG gating. The investigators will aim to establish the normalcy of T1 dispersion curves for left ventricular myocardium in healthy volunteers, and further on to distinguish the characteristics of post-myocardial infarction scar T1 dispersion curves.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: July 31, 2025
• Est. primary completion date: July 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Participant who is willing and able to give informed consent for participation in the study

• Healthy volunteers willing to give informed consent for participation in the study

• Patients diagnosed with a previous myocardial infarction

Exclusion Criteria:

• Unwillingness to participate

• Claustrophobia

• Contraindication to MRI scanning such as implantable cardiac devices

• Participants who have had a previous myocardial infarction in the past of which they may not be aware and this is discovered whilst being scanned on the 3T MRI scanner, or who may have any other cardiology condition that they were previously unaware will not be included in the healthy control group, even if they present themselves to us as "healthy" at the time of the study visit

• Pregnancy

• Body habitus that may preclude comfortable positioning of the volunteer in either of the MRI scanners (>50cm in diameter)

• Participants with abnormal kidney function that will preclude them from receiving a contrast agent

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction

Intervention

Procedure:
• Cardiac Magnetic Resonance Imaging
Cardiac Magnetic Resonance Imaging - Cardiac Scan
• Fast Field Cycling - Magnetic Resonance Imaging
Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
• Electrocardiogram
Electrocardiogram
• Echocardiogram
Echocardiogram

Locations

Country	Name	City	State
United Kingdom	Cardiovascular Research Facility	Aberdeen	Aberdeenshire
United Kingdom	University of Aberdeen and NHS Grampian	Aberdeen	Aberdeenshire

Sponsors (1)

Lead Sponsor	Collaborator
University of Aberdeen

Country where clinical trial is conducted

United Kingdom, 

References & Publications (6)

Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, Margaritis M, Shirodaria C, Kampoli AM, Akoumianakis I, Petrou M, Sayeed R, Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, Antoniades C. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017 Jul 12;9(398):eaal2658. doi: 10.1126/scitranslmed.aal2658. — View Citation

Broche LM, Ashcroft GP, Lurie DJ. Detection of osteoarthritis in knee and hip joints by fast field-cycling NMR. Magn Reson Med. 2012 Aug;68(2):358-62. doi: 10.1002/mrm.23266. Epub 2011 Dec 12. — View Citation

Broche LM, Ismail SR, Booth NA, Lurie DJ. Measurement of fibrin concentration by fast field-cycling NMR. Magn Reson Med. 2012 May;67(5):1453-7. doi: 10.1002/mrm.23117. Epub 2011 Oct 24. — View Citation

Broche LM, Ross PJ, Pine KJ, Lurie DJ. Rapid multi-field T(1) estimation algorithm for Fast Field-Cycling MRI. J Magn Reson. 2014 Jan;238:44-51. doi: 10.1016/j.jmr.2013.10.010. Epub 2013 Oct 31. — View Citation

Kimmich R, Nusser W, Winter F. In vivo NMR field-cycling relaxation spectroscopy reveals 14N1H relaxation sinks in the backbones of proteins. Phys Med Biol. 1984 May;29(5):593-6. doi: 10.1088/0031-9155/29/5/011. No abstract available. — View Citation

Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, Spath N, Yucel-Finn A, Yuecel R, Oldroyd K, Dospinescu C, Horgan G, Broadhurst P, Henning A, Newby DE, Semple S, Wilson HM, Dawson DK. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy. Circulation. 2019 Mar 26;139(13):1581-1592. doi: 10.1161/CIRCULATIONAHA.118.037975. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiac Magnetic Resonance Imaging	Cardiac Magnetic Resonance Imaging - Cardiac Scan to assess cardiac function and T1 dispersion curves	At baseline
Primary	Fast Field Cycling Magnetic Resonance Imaging	Fast Field Cycling Magnetic Resonance Imaging - Cardiac Scan to assess cardiac function and T1 dispersion curves	At baseline